Preclinical & Clinical Assets

Biocytogen is dedicated to the discovery and development of novel antibody-based drugs to meet unmet medical needs, with a particular focus on oncology, autoimmune, inflammatory, metabolic, and other diseases. The company’s current assets include monoclonal antibodies, bispecific antibodies, bispecific ADCs, etc. By advancing its R&D capabilities and establishing key partnerships for licensing and co-development opportunities, Biocytogen aims to deliver transformative therapies to patients in need.

To learn more about our assets, or to explore licensing/co-development opportunities. please contact [email protected].

Therapeutic Area

Product

Target(s)

Partner

Molecular Format

Indication(s)

Status



Oncology
 
 
 

 


YH003
CD40
  mAb Solid tumors Phase 2
YH001
CTLA-4
TRACON mAb Solid tumors Phase 1->Phase 2
YH002
OX40
mAb Solid Tumors Phase 1
YH004

4-1BB

  mAb Solid tumor + Hematological malignancy Phase 1
YH008
PD-1 x CD40
Chipscreen NewWay BsAb Solid tumors Phase 1
YH012 HER2 x TROP2   BsADC Solid tumors Pre-clinical
YH013 EGFR x MET   BsADC Solid tumors Pre-clinical
YH016
Undisclosed
    Oncology Discovery
TNFR2 Dragonboatbio mAb Solid tumors IND
BCG008 SIGLEC15 Undisclosed mAb Solid tumors Pre-clinical
BCG011 TROP2 x EGFR Doma BsADC  Oncology  Pre-clinical 
BCG012 HER3 x MUC1 Doma BsADC  Oncology  Pre-clinical
B7-H3 Mabworks mAb Solid tumors Discovery
BCG005
CCR8
LiberoThera mAb  Solid tumors Discovery
AMHR2 Undisclosed mAb Solid tumors Discovery
BCG006 WT1 Undisclosed TCRm Oncology Discovery
BCG010
NKG2A
Undisclosed mAb Oncology Discovery
BCG013 5T4 x MET Doma BsADC Oncology Discovery
Inflammation and Autoimmunity

CD40 inhibitor mAb Autoimmunity Pre-clinical
YH017
Undisclosed     Autoimmunity Discovery
Infectious Diseases
BCG004
Rabies virus Undisclosed mAb Infectious Diseases Discovery
Rare Diseases
BCG009
Undisclosed Undisclosed mAb Rare Diseases Discovery

Learn more about our antibody hits library here.

Back to top